Healthcare Industry News: Thermo Fisher Scientific
News Release - January 10, 2019
GigaGen Announces Appointment of Erica Stone, Ph.D., as Director, Immuno-OncologyDr. Stone will lead GigaGen's immuno-oncology research and discovery of first-in-class monoclonal antibody therapies
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2019 -- (Healthcare Sales & Marketing Network) -- GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that Erica Stone, Ph.D., has joined the company as director, immuno-oncology.
"The field of immuno-oncology is producing therapies that are immensely powerful for some cancer patients," said Dr. Stone. "GigaGen leads the industry with their innovative antibody discovery technology that allows new insight into immune system function. I look forward to using these insights to better understand the biological mechanisms behind cancer resistance to existing therapies so that we can identify new first-in-class treatments for patients."
Prior to joining GigaGen Dr. Stone served as an assistant professor in the Immunology, Microenvironment and Metastasis Program at The Wistar Institute, a world leader in early-stage discovery science in the areas of cancer, immunology and infectious disease. Her laboratory focused on understanding mechanisms of action of first-generation immune checkpoint inhibitors including anti-CTLA4.
Dr. Stone received her Ph.D. in Biological Sciences from UC San Diego where she also completed a postdoctoral fellowship in the Laboratory of Stephen Hedrick working on T-cell differentiation and function. Dr. Stone's work is widely published in leading peer-reviewed journals and she has received multiple investigative grants and awards including the Chambers-Thermo Fisher Scientific Memorial Award from the American Association of Immunology (AAI).
GigaGen is a privately-held, preclinical biopharmaceutical company developing novel antibody therapies to treat diseases of immune dysregulation. GigaGen's deep understanding of immune dysregulation is enabled by industry-leading technology that quickly captures the genetic makeup of entire immune repertoires to analyze B cells at a rate of millions per hour, while simultaneously identifying their antigen and protein binders. GigaGen has a robust internal pipeline consisting of novel antibodies against immuno-oncology targets, in addition to the first recombinant intravenous immunoglobulin (IVIG) for patients with immune deficiency. For more information visit www.GigaGen.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.